UBS lowered the firm’s price target on Enhabit (EHAB) to $8.50 from $10 and keeps a Neutral rating on the shares. Enhabit’s Q2 results were largely positive, but the company is focused on combating the home health rate cut, the analyst tells investors in a research note.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EHAB: